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We developed a real-time reverse transcription–-
PCR that detected 1,164 copies/mL of Crimean-Congo 
hemorrhagic fever virus per milliliter of serum at 95% prob-
ability (probit analysis) and was 100% concordant with nest-
ed PCR on 63 samples from 31 patients with conﬁ  rmed in-
fection. Infected patients who died appeared to have higher 
viral loads; low viral loads correlated with IgG detection.
C
rimean-Congo hemorrhagic fever (CCHF) is a tick-
borne viral zoonosis that occurs widely in Africa, Asia, 
and Eastern Europe. It is caused by CCHF virus (CCHFV), 
a segmented, negative-stranded RNA virus belonging to 
the family Bunyaviridae, genus Nairovirus. CCHF has a 
fatality rate of ≈30% and a potential for nosocomial spread 
(1). Early diagnosis of CCHF is important for case manage-
ment and protection of medical staff.
Diagnostic assays for CCHF include virus culture, an-
tigen-detection enzyme immunoassay (EIA), antibody-de-
tection EIA, and reverse transcription–PCR (RT-PCR) (2). 
Virus detection is the main diagnostic method in the acute 
stage of disease, and RT-PCR is most sensitive method of 
detection. However, because of the remarkable genetic vari-
ability among CCHFV strains, all current RT-PCRs either 
lack sensitivity or focus on the detection of local CCHFV 
variants only (3–6).
We describe the ﬁ  rst real-time RT-PCR that rapidly 
and reliably detects the global spectrum of clinically rel-
evant virus strains. An extended strategy of probe design 
was implemented to cover such high variability. Sensitivity 
was demonstrated by testing virus strain collections from 
several different Biosafety Level 4 laboratories, essential-
ly covering the full range of global diversity of CCHFV   
(Figure 1). A comprehensive panel of original clinical 
samples from persons with conﬁ  rmed cases of CCHF was 
used for clinical evaluation; the samples were collected by 
World Health Organization reference facilities.
The Study
Primers and probes were selected on the basis of an 
alignment of S segment sequences of 61 CCHFV isolates 
from all known CCHF-endemic regions worldwide (7) 
(representative sequences shown in expanded online ver-
sion of Figure 2, available from www.cdc.gov/EID/content/ 
13/7/1097-G2.htm). Oligonucleotide melting points, fold-
ing characteristics, and cross-hybridization properties were 
determined by using the Primer Express software package 
(Applied Biosystems; Foster City, CA, USA). Primers 
were selected to amplify a 181-bp region near the 5′-end of 
the S segment. The capability of these primers to amplify 
12 representative CCHFV strains from distinct CCHF-en-
demic regions was conﬁ  rmed initially by gel detection RT-
PCR (data not shown) (Figure 2, expanded online version, 
panel B).
For real-time PCR, identifying a simple detection 
probe compatible with all known CCHFV strains was not 
possible. Therefore, a broad-range probe was formulated 
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Figure 1. Global distribution and phylogenetic relationships of 
Crimean-Congo hemorrhagic fever virus (CCHFV) strains selected 
for design and validation of the assay. All strains except those 
marked with asterisks were tested. Phylogenetic analysis was 
based on available 450-bp sequences (from the National Center 
for Biotechnology Information) of CCHFV small (S-) segment 
and generated by the neighbor-joining method with TreeCon for 
Windows (version 1.3b; Yves van de Peer, University Konstanz, 
Germany). Nomenclature of CCHFV clades is based on (7). Note 
that group VII can be resolved only when analyzing the M-segment, 
not the S-segment as shown here. *These CCHFV strains are 
shown for reference, but they were not available for testing. **This 
strain was not available; however, strain Kosovo, which is almost 
identical, was tested instead. ***Strain AP92 has also not been 
available for testing. It was isolated from a Rhipicephalus bursa tick 
and has never been associated with human disease. DISPATCHES
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on the basis of the observation that the non–Watson/Crick 
base pair G:T is almost as thermodynamically stable as 
regular Watson/Crick base pairs, whereas A:C is very un-
stable (8). Thus, the probe was placed on the DNA strand 
that provided more G:T mismatches than complementary 
A:C mismatches, and the resulting G:T mismatches were 
not compensated for. As shown in the left panel of Figure 
2B (see expanded online version), this probe, designated 
SE01, detected all 12 representative strains. Because signal 
intensity varied according to the strain detected, a strain 
that provided low signal (BT956, Figure 2B expanded on-
line version, left panel) was chosen for evaluation of sensi-
tivity. Its full S segment RNA was cloned and transcribed 
in vitro to obtain a quantitative RNA standard (9). Cloning, 
in vitro transcription, puriﬁ  cation, and quantiﬁ  cation were 
performed as previously described (10). End-point dilution 
showed that single copies of RNA could be detected de-
spite low overall ﬂ  uorescence (data not shown). Neverthe-
less, variation in signal intensity between strains was ad-
justed by the following 2 modiﬁ  cations. First, an additional 
oligonucleotide (SE03) was introduced at the same binding 
site as SE01. This probe had 2 effects: ﬁ  rst, a pyrimidine 
base (IUB-code “Y,” 50% C and 50% T) was generated 
at 2 positions of balanced C/T polymorphisms. Second, a 
“keto” base (IUB-code “K,” 50% G and 50% T) resulted at 
1 position of total variability (A, C, G, T). RNA from the 12 
representative strains was tested, and those strains that still 
provided low signal were realigned separately. On the basis 
of the second alignment, an additional probe was selected 
at an alternative binding site to prevent interference with 
probes at the ﬁ  rst binding site. It was placed on the minus 
strand to obtain more G:T mismatches than complementary 
A:C mismatches (see above). The improvement obtained 
by the additional probes on the set of representative strains 
is shown in Figure 2B, middle panel (expanded online ver-
sion). The ﬁ  nal assay protocol is summarized in the Table. 
For precise evaluation of analytical sensitivity, a se-
ries of human plasma samples was spiked with the RNA 
standard from strain BT-958 in concentrations ranging 
from 100,000 to 10 copies per mL. Testing was done on 
5 replicate reactions per concentration, and probit analysis 
was conducted as shown in the expanded online version 
of Figure 2, panel B, right graph (11). The calculated limit 
of detection, deﬁ  ned as the concentration down to which 
>95% of conducted tests can be expected to be positive, 
was 13.6 copies per reaction (p = 0.05). This corresponded 
to 1,164 copies per mL of plasma (95% conﬁ  dence interval, 
780–2990 copies/mL).
Cross-reactivity was excluded by testing DNA or 
RNA from cultures or high-titered clinical samples con-
taining Dugbe virus, Rift Valley fever virus, Sudan Ebola-
virus Gulu, Lassa virus AV, yellow fever virus, dengue vi-
rus types 1–4, Japanese encephalitis virus, West Nile virus 
Uganda, Venezuelan equine encephalitis virus, Sindbis vi-
rus, Ross River virus, Epstein-Barr virus, hepatitis C virus, 
human cytomegalovirus, monkeypox virus, poliomyelitis 
virus types 1–3, rabies virus RSDD, Bacillus anthracis, 
Leptospira interrogans, Listeria monocytogenes, Neisse-
ria meningitidis, Coxiella burnetii, Rickettsia prowazekii, 
R. rickettsii, and Plasmodium falciparum. An additional 
Figure 2. Clinical evaluation. Upper panel: plasma viral load over 
time in 44 samples from 17 patients. Samples from patients who 
died are marked with a ﬁ  lled square. Lower panel: plasma viral load 
in relation to antibody status in 16 samples with and 27 samples 
without detectable immunoglobulin G (IgG) antibodies. Only IgG 
status was taken as reference because only 2 patients had IgM 
without IgG. The difference of means between the 2 groups was 
highly signiﬁ  cant (t test, p = 0.00005). Boxes indicate 25th through 
75th percentiles; error bars indicate 5th and 95th percentiles.. An 
expanded online version of this ﬁ  gure is available from www.cdc.
gov/EID/content/13/7/1097-G2.htm. Crimean-Congo Hemorrhagic Fever Virus Patients
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128 blood specimens collected during the course of the 
study from 128 patients with conditions other than CCHF 
all tested negative for CCHF virus. 
The real-time RT-PCR was used to test and quantify 
63 serum samples from 31 patients with laboratory-con-
ﬁ  rmed CCHFV infection; the samples were obtained 1–18 
days after symptom onset. All samples had nested RT-PCR 
results positive for CCHFV (3), and all were also positive 
by the new real-time RT-PCR. For 21 patients with con-
ﬁ  rmed CCHF (17 from South Africa, 3 from Iran, and 1 
from Pakistan), viral load was quantiﬁ  ed and compared 
with other standard diagnostic methods for CCHFV de-
tection (online Appendix Table, available from www.cdc.
gov/EID/content/13/7/1097-appT.htm). Again, sensitivity 
of the new assay was at least as high as that of nested PCR. 
As shown in Figure 2, there was a clear correlation between 
viral load and duration of symptoms in these patients. Clin-
ical outcome could not be correlated clearly with viral load, 
although patients who died of the disease seemed, in gen-
eral, to have higher viral loads (Figure 2, ﬁ  lled squares). 
The appearance of antibodies correlated clearly with lower 
viral loads (Figure 2).
Conclusions
To our knowledge, this is the ﬁ  rst PCR validated with 
representative CCHFV strains from nearly all regions 
worldwide where the virus is endemic. High sensitivity en-
ables reliable detection of virus in early stages of the infec-
tion, when antibody detection is unreliable or impossible. 
By eliminating the need for postampliﬁ  cation product pro-
cessing, real-time RT-PCR enables shortened turnaround 
times for reporting results, which is critical for deciding 
on isolation and contact-tracing for suspected case-pa-
tients. Quantiﬁ  cation of viral load may assist in estimating 
the patient’s infectivity. It may also assist in predicting the 
clinical outcome and could be used to monitor viral load 
in patients receiving ribavirin treatment (12). Our study 
provides baseline data on CCHF viral load throughout the 
acute stage of the illness. High viral load tended to indicate 
fatal outcome, and lower viral load was generally associat-
ed with detectable antibodies. Because detectable antibody 
response correlates with good outcome (13), viral load will 
probably be a useful predictor of clinical progress. These 
preliminary data are highly encouraging for further studies 
on larger patient cohorts.
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